Skip to main content
OpenTrials
Completed

NCT Number: NCT02160574

Safety Study to Evaluate the Cumulative Irritation Potential of Topically Applied ZuraPrep™ and ZuraPrep™ Without IPA

This is a safety study to determine the cumulative skin irritation potential of ZuraPrep™ and ZuraPrep™ without Isopropyl Alcohol after repetitive patch applications to skin of human subjects.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

BioScience Laboratories

Bozeman, Montana, 59718, United States

About this study

This cumulative irritation evaluation is designed to determine the skin irritation potential of ZuraPrep™ and ZuraPrep™ without Isopropyl Alcohol (IPA) after repetitive patch application to skin of healthy human subjects.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects may be of either sex, at least 18 years of age and of any race
  • Subjects must be free of tattoos, sunburn, dermatoses, cuts, lesions or other disorders of the skin of the back.
  • Subjects must be in good general health

Exclusion criteria

  • Known allergies to latex, metals, tape and/or adhesives, soap, citric acid, methylene blue, methylparaben, propylparaben, chlorhexidine gluconate, isopropyl alcohol, and sodium lauryl sulfate.
  • Exposure of the back region to antimicrobial agents, medicated soaps, medicated shampoos, medicated lotions, strong detergents, sun-tanning, use of tanning beds, or swimming or soaking in pools or hot tubs, in the 7 days prior to, or during the 3-week test period.
  • Use of topical or systemic corticosteroid, antihistamine, or anti-inflammatory medications in the 7 days prior to, or during the 3-week test period.
  • Current or recent severe illness such as asthma, diabetes, hepatitis, organ transplant, mitral valve prolapse, congenital heart disease, internal prostheses, or any immunocompromised condition such as AIDS or HIV positive.
  • Pregnancy, plans to become pregnant, breast-feeding
  • Any active skin rash or breaks in the skin of the back
  • Any sunburn or tattoos on the skin of the back
  • Current active skin disease or inflammatory skin condition including contact dermatitis
  • Participation in a clinical study in the past 7 days or current participation in another clinical study
  • Any medical condition or use of any medications that, in the opinion of the Principal Investigator, would preclude participation
  • Unwillingness to fulfill the performance requirements of the study

Treatment and study plan

Chloraprep

Drug

The degree of skin irritation caused by ChloraPrep will be graded and compared to ZuraPrep and ZuraPrep without IPA.

Other names: Reference Product, 2% Chlorhexidine Gluconate and 70% IPA

0.1% Sodium Lauryl Sulfate

Drug

The degree of skin irritation caused by 0.1% Sodium Lauryl Sulfate will be graded and compared to ZuraPrep and ZuraPrep without IPA.

Other names: Positive Control

0.9% Physiological Saline

Drug

The degree of skin irritation caused by 0.9% Physiological Saline will be graded and compared to ZuraPrep and ZuraPrep without IPA.

Other names: Negative Control

ZuraPrep without IPA

Other

Results from exposure to ZuraPrep will be compared statistically those from exposure to ZuraPrep without IPA

Other names: ZuraPrep without Isopropol Alcohol (IPA)

Primary outcomes

  1. Scoring Scale (0-7) for Visual Evaluation of Skin Condition

    Time frame: 0-21 days post dose

    Results from skin scores of ZuraPrep and ZuraPrep without IPA will be compared statistically, and both will be compared to the Positive Control (0.1% Sodium Lauryl Sulfate).

Secondary outcomes

  1. Scoring Scale (0-7) for Visual Evaluation of Skin Condition

    Time frame: 0-21 days post dose

    The degree of skin irritation caused by the Reference Product (ChloraPrep) and the Negative Control (0.9% Physiological Saline) will be graded.

Sponsors and collaborators

Lead sponsor

Zurex Pharma, Inc.

Industry

Registry information

Official study title

A 21-Day Evaluation of the Cumulative Irritation Potential of Topically Applied ZuraPrep™ and ZuraPrep™ Without IPA in Healthy Adult Volunteers

Important dates

Study start
2014
Primary completion
2014
Study completion
2014
First posted
Jun 10, 2014
Registry last updated
Oct 27, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.